Marico Limited Annual Profit Rises to ₹1,813 Crore for FY 2025-26

Marico Limited has announced its financial results for the year ended March 31, 2026, reporting a strong performance with a consolidated net profit of ₹1,813 crore. The company saw significant revenue growth, reaching ₹13,611 crore for the year. Additionally, the Board has recommended a final dividend of ₹4.00 per share. The company continues to expand its portfolio through strategic acquisitions, including Zea Maize and Cosmix, to bolster its global presence.

Annual Financial Highlights

For the financial year 2025-26, Marico Limited demonstrated robust growth, with consolidated revenue from operations climbing to ₹13,611 crore, compared to ₹10,831 crore in the previous year. The consolidated net profit for the year stood at ₹1,813 crore, reflecting an increase from the ₹1,658 crore reported in 2024-25. Basic earnings per share (EPS) for the year reached ₹13.62.

Dividend and AGM Announcement

The Board of Directors has recommended a final equity dividend of ₹4.00 per equity share of Re. 1 face value for the financial year 2025-26. This proposal is subject to approval by shareholders at the company’s 38th Annual General Meeting (AGM), which is scheduled to be held on August 6, 2026. Shareholders of record as of July 30, 2026, will be entitled to this dividend, with payouts expected by September 5, 2026.

Strategic Growth and Acquisitions

Marico continues to actively broaden its reach through strategic investments. During the final quarter of the year, the company acquired a 93.27% stake in Zea Maize Private Limited (owner of the 4700BC brand) and a 60% stake in Cosmix Wellness Private Limited. These acquisitions align with the company’s focus on diversifying its beauty and wellness portfolio. Earlier in the fiscal year, the company also increased its stake in Satiya Nutraceuticals (Plix) to 60% and completed the full acquisition of HW Wellness Solutions (True Elements).

Segment Performance

The company operates across two primary segments: India and International. For the year ended March 31, 2026, the India segment recorded revenue of ₹10,348 crore, while the International segment contributed ₹3,263 crore to the total revenue. These results reflect the company’s sustained strategy of balancing core brand performance in the domestic market with expansion efforts in international territories.

Source: BSE

Previous Article

Marico Appointment of Girish Paranjpe as Independent Director

Next Article

Emcure Pharmaceuticals Strong FY26 Performance as Revenue Crosses $1 Billion Milestone